Zymeworks (ZYME) Q1 2025 earnings summary

Executive summary

• Advanced a diversified pipeline of ADCs, T-cell engagers, and multispecific antibodies targeting oncology and autoimmune diseases, with multiple clinical and preclinical programs progressing and a focus on operational discipline and capital efficiency.

• Achieved FDA accelerated approval of zanidatamab (Ziihera®) for HER2-positive BTC in the US, with EMA and China regulatory reviews ongoing and a positive CHMP opinion in Europe.

• Revenue increased 171% year-over-year to $27.1 million in Q1 2025, driven by milestone payments from GSK and Daiichi Sankyo.

• Cash resources totaled $321.6 million as of March 31, 2025, with a projected runway into the second half of 2027.

• Presented six posters at AACR, highlighting innovation in multi-specific antibodies and ADCs, and appointed Dr. Sabeen Mekan as SVP of Clinical Development.

Financial highlights

• Q1 2025 revenue was $27.1 million, up from $10.0 million in Q1 2024, mainly from $14.0 million GSK and $3.1 million Daiichi Sankyo milestones, and $0.2 million in royalties from Jazz.

• Net loss for Q1 2025 was $22.6 million, an improvement from $31.7 million in Q1 2024, with net loss per share improving to $(0.30) from $(0.42).

• Operating expenses rose to $52.7 million, with R&D at $35.7 million and G&A at $17.0 million, mainly due to increased stock-based compensation.

• Operating cash outflow was $3.4 million, a significant improvement from $37.7 million in Q1 2024.

• Cash, cash equivalents, and marketable securities totaled $321.6 million as of March 31, 2025.

Outlook and guidance

• Cash resources expected to fund operations into the second half of 2027, covering multiple pipeline catalysts and anticipated regulatory milestones.

• IND submissions planned for ZW251 (mid-2025), ZW209 (1H 2026), and ZW1528 (2H 2026); pivotal Phase 3 data for zanidatamab in 1L GEA anticipated 2H 2025.

• Regulatory decisions for zanidatamab in EU and China expected in 2025; Jazz may launch zanidatamab for 1L GEA in 2026.

• Anticipates increased royalty revenue if zanidatamab is approved in Europe for HER2-positive BTC.

• Continued expansion into hematology oncology and AIID, with a focus on solid tumors and digestive system cancers.